You are viewing the site in preview mode

Skip to content


  • Poster presentation
  • Open Access

Development of Efavirenz nanoparticle for enhanced efficiency of anti-retroviral therapy against HIV and AIDS

BMC Infectious Diseases201212 (Suppl 1) :P7

  • Published:


  • Drug Release
  • Efavirenz
  • Entrapment Efficiency
  • Cell Uptake
  • Water Soluble Drug


The FDA approved drug Efavirenz is a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) successful first line drug of choice in Highly Active Anti-Retroviral Therapy (HAART) for treatment of HIV and AIDS. It is poorly water soluble drug (10 g/ml) with 40-45% of bioavailability and administered as high doses 600-800 mg/day. Increase in solubility can enhance bioavailability; providing reduction of dose, resistance and harmful side effects.


Efavirenz nanoparticles are developed using methacrylate polymers (Eudragit E100) by emulsion solvent evaporation method (1:0.5, 1:1, 1:2 and 2:1 ratios) and the in-vitro evaluations such as particle size, morphology, solubility changes, drug release, compatibility and cytotoxicity tests are carried out.


The particle size of 99-200 nm with narrow size distribution and surface charge (-52 V) shows high stability. The formulation with entrapment efficiency (75-90%) shows higher drug release profile 95-100% within 1 hour compared to 23%-58% of pure drug in water, 0.1N HCl and phosphate buffer pH 7.4 media. The DSC, TG-DSC, powder XRD and SEM morphology results reveal that there is solid transition from crystalline structure to amorphous state, which supports the solubility enhancement. The FT-IR gives the compatibility results for drug with other excipients. The Efavirenz nanoparticles subjected for in-vitro cytotoxicity and cell uptake studies using monocytes / macrophages (THP-1) proved better uptake (Flocytometry and Confocal microscope) of nanoparticles than free drug.


The solubility enhancement due to nanosizing helps in hastening the drug release and also increasing cell uptake, which helps in attaining high bioavailability with low dose of Efavirenz.

Authors’ Affiliations

Department of Pharmacy, School of Chemical and Bio-Technology, SASTRA University, Thanjavur, 613 401, Tamil Nadu, India
Department of Pharmaceutics, Madras Medical College, Chennai, 600001, Tamil Nadu, India


© Hari et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.